TROP-2, 5hmC, and IDH1 Expression in Anaplastic Thyroid Carcinoma.

Jae Yeon SeokKristine AstvatsaturyanMariza De Peralta-VenturinaJinping LaiXuemo Fan

Published in: International journal of surgical pathology (2020)

Increased TROP-2 immunoexpression in some ATCs supports that these patients may potentially benefit from an antibody-drug conjugate therapy targeting TROP-2. Markedly reduced 5hmC expression suggests that 5hmC may be used as potential therapeutic targets for ATC. The total lack of IDH1 R132H mutation by immunostain indicates that it has no prognostic and therapeutic value in ATC.

Keyphrases

poor prognosis
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
cancer therapy
low grade
binding protein
stem cells
patient reported outcomes
drug delivery
risk assessment
bone marrow
cell therapy